The North American preventive inhaler market was $3.5 billion in 2018 and is anticipated to grow at a substantial rate of 1.0% during the forecast period. The major factors that are contributing significantly to the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The US and Canada are the major economies of North America. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the inhaler market in the North America region. The increasing demand for inhaler due to increasing COPD and asthma patients in the US has endorsed the approval of cohesive reimbursement policies in the US, is further fueling the growth of the market. The US is the major market due to greater healthcare expenditure and a higher prevalence rate of respiratory diseases.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/north-american-preventive-inhaler-market
The North American preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device type, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the North American preventive inhaler market due to providing an easy inhalation solution. Whereas, the market for metered dose inhaler is estimated to be the fastest-growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/north-american-preventive-inhaler-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing inhalers to cater to a wide range of customers within the region and across the globe. The major players of the North American preventive inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp. (Propeller Health), Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Market Segmentation
North American Preventive Inhaler Market by Device Type
- Metered Dose Inhaler
- Dry Powder Inhaler
North American Preventive Inhaler Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
North American Preventive Inhaler Market by End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- US
- Canada
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- Aradigm Corp.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Drive Devilbiss Healthcare LLC
- GlaxoSmithKline PLC
- Koninklijke Philips N.V.
- Manta Devices LLC
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Teva Pharmaceuticals Industries Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
